COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

30,844 Articles (22,553 medRxiv, 8,291 bioRxiv)

Most recent first Previous |  Page 317: Articles 3161-3170  | Next

Protection conferred by COVID-19 vaccination, prior SARS-CoV-2 infection, or hybrid immunity against Omicron-associated severe outcomes among community-dwelling adults
Lee, N., Nguyen, L., Austin, P. C., Brown, K. A., Grewal, R., Buchan, S. A., Nasreen, S., Gubbay, J., Schwartz, K. L., Tadrous, M., Wilson, K., Wilson, S. E., Kwong, J. C.
10.1101/2023.08.24.23294503 — Posted: 2023-08-25
Risk factors for SARS-Cov-2 infection at a United Kingdom electricity-generating company: a test-negative design case-control study
Rutter, C. E., Van Tongeren, M. J., Fletcher, T., Rhodes, S. E., Chen, Y., Hall, I., Warren, N., Pearce, N.
10.1101/2023.08.25.23294609 — Posted: 2023-08-25
RCT-based Social Return on Investment (SROI) of a home exercise programme for people with early dementia comparing in-person and blended delivery before and during the COVID-19 pandemic
Doungsong, K., Hartfiel, N., Gladman, J., Harwood, R. H., Edwards, R. T.
10.1101/2023.08.25.23294408 — Posted: 2023-08-25
Efficient Sequence Embedding For SARS-CoV-2 Variants Classification
Ali, S., Sardar, U., Khan, I., Patterson, M.
10.1101/2023.08.24.554650 — Posted: 2023-08-25
Mucosal antibody responses to SARS-CoV-2 booster vaccination and breakthrough infection
Bhavsar, D., Singh, G., Sano, K., Gleason, C., Srivastava, K., Carreno, J. M., Simon, V., Krammer, F.
10.1101/2023.08.24.554732 — Posted: 2023-08-25
Antibody Neutralization of Emerging SARS-CoV-2: EG.5.1 and XBC.1.6
Wang, Q., Guo, Y., Zhang, R. M., Ho, J., Mohri, H., Valdez, R., Manthei, D. M., Gordon, A., Liu, L., Ho, D. D.
10.1101/2023.08.21.553968 — Posted: 2023-08-25
Gender differences in submission behavior exacerbate publication disparities in elite journals
Basson, I., Ni, C., Badia, G., Tufenkji, N., Sugimoto, C. R., Lariviere, V.
10.1101/2023.08.21.554192 — Posted: 2023-08-25
Divergence of variant binding/neutralizing antibodies following SARS-CoV-2 booster vaccines in myeloma: Impact of hybrid immunity
Moreno, A., Manning, K., Azeem, M. I., Nooka, A. K., Ellis, M., Manalo, R. J., Switchenko, J. M., Wali, B., Kaufman, J. L., Hofmeister, C. C., Joseph, N. S., Lonial, S., Dhodapkar, K. M., Dhodapkar, M. V., Suthar, M. S.
10.1101/2023.08.17.553767 — Posted: 2023-08-25
Rationally designed multimeric nanovaccines using icosahedral DNA origami for molecularly controlled display of SARS-CoV-2 receptor binding domain
Feng, Q., Cheng, K., Zhang, L., Gao, X., Liang, J., Liu, G., Ma, N., Xu, C., Tang, M., Chen, L., Wang, X., Ma, X., Zou, J., Shi, Q., Du, P., Wang, Q., Nie, G., Zhao, X.
10.1101/2023.08.24.554561 — Posted: 2023-08-24
SARS-CoV-2 Nsp13 is a viral RHIM protein promoting cell death linked to Z-RNA sensing and ZBP1-RIPK3 signaling
Mishra, S., Jain, D., Dey, A. A., Nagaraja, S., Srivastava, M., Khatun, O., Balamurugan, K., Anand, M., Tripathi, S., Ganji, M., Kesavardhana, S.
10.1101/2023.08.23.554434 — Posted: 2023-08-24

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).